Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation
Multiple myeloma is a cancer that arises from a type of white blood cells called as plasma cell myeloma. Plasma cells become abnormal, proliferate when tumors accumulate in the different parts of the body especially in the bone marrow. Myeloma is diagnosed and monitored by measuring the levels of paraproteins. Amyloidosis is a rare disease that occurs when an abnormal protein called amyloid builds up in your organs and interferes with their normal function. Amyloid is formed from several different types of protein in the body. Treatments for amyloidosis may include medications to reduce amyloid production and to control symptoms and some people may benefit from organ or stem cell transplants. A stem cell transplant also called a bone marrow transplant which treats certain types of cancer. Depending on where the stem cells come from the transplantation is defined either peripheral stem cell transplant or cord blood transplant. Hemopoietic stem cells give rise to other blood substances by a process called Hemopoiesis in the red bone marrow. Hemopoietic stem cell transplants are used in the treatment of immune system disorders and cancers.
Related Conference of Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation
Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation Conference Speakers
Recommended Sessions
- Blood Disorders Diagnosis & Treatment
- Blood Transfusion
- Case reports of Hematology
- Cell Therapy
- COVID-19 and Hematology
- Disorders of Vascular Bleeding
- Hematology
- Hematology Oncology
- Immunohematology
- Leukaemia and Lymphoma
- Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation
- New Drug Development in Hematology
- Patient Blood Management
- Pediatric Hematology
- Stem Cell Research
- Thalassemia
- Therapeutic Apheresis
- Thrombosis and Coagulation
- Transfusion Medicine
- Transfusion Transmissible Infections
Related Journals
Are you interested in
- Bleeding Disorders in Women - Blood Disorders 2024 (Ireland)
- Digital Health and Artificial Intelligence (AI) in Hematology - Blood Disorders 2024 (Ireland)
- Hematologic Gene Editing and Gene Therapies - Blood Disorders 2024 (Ireland)
- Hematology and Stem Cell Research - Blood Disorders 2024 (Ireland)
- Hematopoietic Stem Cell Transplantation - Blood Disorders 2024 (Ireland)
- Hemoglobinopathies and Sickle Cell Disease - Blood Disorders 2024 (Ireland)
- Hemophilia Management and Research - Blood Disorders 2024 (Ireland)
- Hemostasis and Thrombosis - Blood Disorders 2024 (Ireland)
- Immunotherapy and Hematology - Blood Disorders 2024 (Ireland)
- Leukemia and Lymphoma - Blood Disorders 2024 (Ireland)
- Medicine in Hematology - Blood Disorders 2024 (Ireland)
- Molecular Hematology - Blood Disorders 2024 (Ireland)
- Myelodysplastic Syndromes (MDS) and Bone Marrow Failure - Blood Disorders 2024 (Ireland)
- Next-Generation Diagnostics and Imaging - Blood Disorders 2024 (Ireland)
- Novel Therapies for Blood Cancers - Blood Disorders 2024 (Ireland)
- Pediatric Hematology - Blood Disorders 2024 (Ireland)
- Platelet Disorders - Blood Disorders 2024 (Ireland)
- Sickle Cell Disease (SCD) - Blood Disorders 2024 (Ireland)
- Thalassemia Management - Blood Disorders 2024 (Ireland)
- Transfusion Medicine and Blood Banking - Blood Disorders 2024 (Ireland)